Can You Take Semaglutide While Breastfeeding? What Each Label Says

Can you take semaglutide while breastfeeding? The honest answer depends on which product you mean, and the dividing line is not where most people expect it to be.

Two products containing semaglutide state that breastfeeding is not recommended. Two others containing the same molecule state nothing of the kind. The difference is not semaglutide. It is an ingredient that exists only in the tablet.

What follows quotes Section 8.2 of each FDA label directly, reports the three human datasets that exist, and is specific about what nobody has measured yet. It reports what published sources say. It is not permission to start, continue or stop anything while you are breastfeeding.

Can you take semaglutide while breastfeeding? It depends on the formulation

Four products cover most of the people asking. Wegovy and Ozempic are semaglutide from Novo Nordisk, and Wegovy now comes as a tablet as well as an injection. Rybelsus is oral semaglutide. Zepbound and Mounjaro are tirzepatide from Eli Lilly, a different molecule that comes up in the same conversation.

Here is what each prescribing label says under Section 8.2, Lactation.

Sources: FDA prescribing information, Section 8.2 Lactation. Wegovy revised 6/2026, Ozempic 5/2026, Rybelsus 1/2026, Zepbound 8/2026, Mounjaro 7/2026.

The split runs between formulations, not between manufacturers or molecules. Most pages online still treat oral semaglutide as Rybelsus alone and have not caught up to Wegovy existing as a tablet that carries the same restriction.

Why the tablet is the one that says no

Semaglutide is a peptide. Swallowed on its own it would be broken down in the stomach before reaching the bloodstream. The oral versions solve that with SNAC, salcaprozate sodium, an absorption enhancer that helps semaglutide cross the stomach lining.

SNAC is the reason the tablet labels treat breastfeeding differently. The label reports that semaglutide itself was below the limit of quantification in human milk samples. SNAC was not. The label states that SNAC and its metabolites are present in human milk, and adds that the activity of enzymes involved in SNAC clearance may be lower in infants compared to adults.

That is the entire basis for the restriction. An infant may clear the additive more slowly than an adult does. The label then points readers toward formulations that do not contain it.

The Wegovy label makes the same point from the other side. It states that Wegovy subcutaneous injection does not contain the SNAC metabolites. Same molecule, different delivery, different lactation advice.

How much human data actually exists

Three datasets, all of them small. Being straight about their size matters more on this topic than on almost any other.

The semaglutide milk study is Diab and colleagues, published in Nutrients in 2024. Eight women taking subcutaneous semaglutide provided milk samples. Semaglutide was not detected in any of the collected human milk samples, against a detection limit of 1.7 ng/mL. The authors calculated a maximum relative infant dose of 1.26 percent, against the 10 percent figure commonly used as a threshold of concern.

The tirzepatide study is the only formal lactation study any of these manufacturers has run. It is worth reporting precisely, because at least one large telehealth page reports it wrongly. Eleven healthy lactating women received a single 5 mg dose. Tirzepatide was undetectable, against a limit of 4 ng/mL, in 164 of 171 milk samples. It was detectable in the remaining seven. Across the sampling window those seven added up to less than 0.02 percent of the dose the mother received, and the last measurable concentration came at five days.

Undetectable in most samples is not undetectable in all of them, and a single 5 mg dose is not ongoing treatment at a higher one.

One detail confuses people who read the labels closely. The Wegovy and Ozempic labels still state that there are no data on the presence of semaglutide in human milk, even though the Diab study measured exactly that. A prescribing label reports the data the manufacturer generated and submitted. Independent academic work does not appear there. So the label and the literature can both be accurate and still say different things, which is one reason LactMed reaches a firmer position than either label does.

This is also why tirzepatide is not the safer choice by default. Tirzepatide has more published data, which is a different thing from a better safety profile. Neither label describes itself as safe during breastfeeding.

The last row is the one to sit with. No direct evidence shows that semaglutide or tirzepatide reduces milk supply. The worry that circulates online is about appetite and calorie intake, which is a separate mechanism and is covered further down.

Where LactMed lands on this

LactMed is the National Institutes of Health Drugs and Lactation Database. It is the reference clinicians actually reach for, and it takes a clearer position than the labels do.

The semaglutide entry, revised 15 August 2026, states: “Only injectable forms of semaglutide should be used during breastfeeding.” It reports eight mothers taking 0.25 to 1 mg weekly whose infants, aged 4 to 23 months, showed normal growth and development.

The tirzepatide entry states: “If a mother requires tirzepatide, it is not a reason to discontinue breastfeeding.” It adds a note of caution where the infant is a newborn or was born preterm.

Both entries close with the same practical advice. Monitor the infant’s growth and developmental milestones closely, and monitor the nutritional status of the person who is breastfeeding.

On effects on milk production, both entries say the same thing. Relevant published information was not found as of the revision date.

No obstetric or breastfeeding body has published guidance

As of September 2026, the American College of Obstetricians and Gynecologists has not published guidance on GLP-1 medication during lactation. Neither has the Academy of Breastfeeding Medicine, whose 37 clinical protocols do not include one.

That absence is worth knowing before you read further afield. When a page tells you what the guidelines recommend here, ask which guidelines. Your provider is working from the labels, LactMed and clinical judgment, which are the same three sources this article uses.

The milk supply worry is really a calorie worry

The theoretical concern with weight loss treatment during breastfeeding is not the medication reaching the baby. It is what happens when appetite drops while calorie demand is higher than usual.

The Centers for Disease Control and Prevention advises an additional 330 to 400 kilocalories per day for well nourished people who are breastfeeding, compared with pre pregnancy intake. A medication whose main effect is reducing how much you want to eat sits in obvious tension with that number.

No authoritative minimum calorie figure for breastfeeding exists. Anyone quoting a floor is inventing it. What can be said is that intake and nutritional status are the two things to watch, which is exactly what LactMed says.

Protein is usually the first thing to fall when appetite drops. If your provider has approved treatment, the GLP-1 protein calculator sets a daily target from your weight, and the TDEE calculator gives a baseline energy figure. Treat both as numbers to bring to your appointment, not a plan to run on your own while breastfeeding.

Starting after birth, and the two month window people confuse it with

The most common practical question is when it is reasonable to start after giving birth. There is no guideline answer.

What exists is expert opinion reported in the press, ranging from waiting until the baby is around nine months old to waiting until breastfeeding has stopped entirely. Those are individual clinicians’ views rather than published guidance, and they deserve to be read that way.

The question is becoming more common. A Danish national analysis published in JAMA in November 2025 found that postpartum GLP-1 prescriptions rose from 34 per 10,000 births in 2022 to 173 per 10,000 in 2024. Fewer than a quarter of those had a documented diabetes diagnosis.

Keep one thing separate. The labels do specify stopping semaglutide at least two months before a planned pregnancy, because of its long half life. That is pregnancy planning guidance. It is not a breastfeeding washout, and it does not mean milk takes two months to clear. We cover it in can you take Ozempic while pregnant and in how long semaglutide stays in your system.

Do you need to pump and discard?

No label and no lactation database supports a pump and discard protocol for semaglutide or tirzepatide. The Wegovy, Ozempic, Rybelsus, Zepbound and Mounjaro labels do not mention one. LactMed does not suggest one for either molecule.

The idea travels because it is familiar from alcohol and from certain imaging agents. It has not been applied to these medications by any source that publishes on lactation. If someone recommends it, it is fair to ask what that recommendation is based on.

Compounded semaglutide sits outside all of this

Every quotation above comes from an FDA approved label for a branded product. Compounded semaglutide and compounded tirzepatide are prepared by state licensed compounding pharmacies. They are not FDA approved and have not been reviewed by the FDA for safety, efficacy or quality. No approved prescribing information exists for them, and no lactation data specific to them exists either.

The molecule is the same. The published data does not transfer automatically, because a compounded preparation is a different product with a different formulation. That makes this a provider conversation, and one where the honest answer includes what is unknown.

What to bring to your provider

A general question about GLP-1 medication and breastfeeding cannot be answered well. Three facts change the answer, so bring all three:

• Which molecule. Semaglutide and tirzepatide have different labels and different evidence behind them.
• Which formulation. Injection and tablet carry different lactation language, and the tablet is the one with the restriction.
• Which product. An FDA approved branded medication has a label. A compounded preparation does not.

Bring your baby’s age and feeding pattern as well. An exclusively breastfed newborn and a mixed fed toddler are different situations, and every published infant report involves infants aged four months and older.

If you want that conversation with a licensed US provider, you can start a free evaluation with Alternate Health Club. Your information is reviewed individually, and a provider will tell you if treatment is not appropriate for you.

Medical Disclaimer

This article is for general educational purposes and is not medical advice. It does not replace a consultation with a licensed healthcare professional or your baby’s clinician. Every label quotation applies to the FDA approved branded product named. Compounded medications are not FDA approved, have not been reviewed by the FDA for safety, efficacy or quality, and carry no approved prescribing information. Do not start, stop or change any medication while breastfeeding without speaking to a qualified provider. Individual circumstances vary and no outcome is guaranteed.